In consultation: Guidance and quality standards
Showing 1 to 10 of 21
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update) | Draft guidance consultation | NICE guideline | |
| Guidance on the use of electroconvulsive therapy | Review proposal consultation | Technology appraisal guidance | |
| Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Baxdrostat for treating uncontrolled or resistant hypertension [ID6623] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Perioperative care in adults | Quality standard consultation | Quality standard | |
| Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249] | Draft guidance | Technology appraisal guidance | |
| Upadacitinib for treating giant cell arteritis [ID6299] | Draft guidance | Technology appraisal guidance | |
| Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388] | Draft guidance | Technology appraisal guidance |